Positive Phase 1b asthma data for zumilokibart; FeNO reduction 60%, durable to 32 weeks; 2026 milestones

Apogee Therapeutics, Inc.

Zumilokibart showed maximum mean FeNO reduction of 45 ppb (60% decrease) after single 720 mg dose; suppression durable through 16 weeks in all patients and up to 32 weeks in some.
Favorable safety profile: no Grade ≥3 TEAEs, SAEs, conjunctivitis, injection site reactions, or anti-drug antibodies; TEAEs included GERD and upper respiratory infection.
Positive trends in FEV1 and Type 2 biomarkers; further data to be presented at medical conferences.
2026 milestones: APEX Part A (AD, 52-week) data Q1; Part B (16-week) data Q2 (347 patients enrolled); Phase 3 AD start 2H 2026; APG279 vs DUPIXENT readout 2H 2026 (80 patients).
Pro forma cash $913M as of Sept 30, 2025; cash runway into 2H 2028 supports advancement to potential 2029 launch.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.